The in-depth Hashimoto's resource · part of the Diabetes & Endocrine Specialists network Call 858-622-7200 Request an appointment
Home › Research and future therapies
Pillar 9 · Research & Future Therapies

Research and future therapies

What is being studied now — from precision dosing to the microbiome to low-dose naltrexone — and how to tell a promising idea from an established treatment. Investigational therapies are presented honestly: neither dismissed nor oversold.

Written by Darius A. Schneider, MD, PhD — President & Medical Director, Diabetes & Endocrine Specialists · Board-Certified Endocrinologist (ECNU)

Key takeaways

  • The most-asked therapies are still investigational — presented honestly, not dismissed or oversold.
  • Precision dosing and novel formulations are the most concrete near-term directions.
  • Low-dose naltrexone has no published outcome data in Hashimoto's, but a controlled trial is now underway.

This section covers what is being studied now, and — just as important — how to tell a promising idea from an established treatment.

Directions in research

Precision dosing (transcriptome / simulation-guided)

Grade D · Experimental
What's shown
Transcriptome profiling and computational simulation are proposed to model individualized replacement; single-cell sequencing is mapping the cells that drive thyroid inflammation.
Stage
Early-stage; promising but not clinical practice.

Sustained-release T3

Grade D · Experimental
What's shown
Novel formulations have passed early-phase (phase 1) safety trials.
Stage
Await efficacy data.

Thyroid regeneration (stem-cell derived)

Grade E · Insufficient
What's shown
Functional thyroid tissue has been grown from stem cells in animal models.
Stage
A long-horizon idea.

Investigational therapies patients ask about

Low-dose naltrexone (LDN)

Grade E · Insufficient
What's shown
No published outcome trials in Hashimoto's — only a plausible immunological rationale and patient-reported experience.
What's changing
A phase 2 randomized, double-blind, placebo-controlled trial (ThyroLDN, ACTRN12625000131459) is testing naltrexone 4.5 mg daily over six months in people with persistent symptoms despite optimal replacement.
Our position
We do not currently offer LDN for Hashimoto's; when ThyroLDN reports we will read it carefully and revise in either direction.

FMT, rituximab, tolerogenic vaccines

Grade E · Insufficient
Evidence
Plausible mechanisms, little or no controlled outcome data in Hashimoto's.
Our position
Unproven; presented as such.

Finding clinical trials

For patients interested in contributing to the evidence rather than getting ahead of it, well-run clinical trials are the route. Our affiliated research center, EndoTrials, runs endocrine studies, and public registries list actively recruiting trials. A dedicated guide is in preparation.

How we grade evidence. Every intervention on this site carries a plain label — from established, guideline-supported care through moderate and conflicting evidence to experimental and insufficient. Mechanistic plausibility is not clinical proof: a laboratory or animal mechanism, or a change in an antibody level, is not the same as a demonstrated improvement in how a patient does.

Questions patients ask

Real questions we hear about immune-modulating and regenerative therapies — answered the way we would answer them in clinic.

Can low-dose naltrexone (LDN) treat Hashimoto’s? Grade E · Insufficient
No proven benefit yet. LDN has no published outcome trials in Hashimoto’s — only a plausible immune rationale — though a controlled trial is now underway.

Why patients ask this

LDN is inexpensive, sounds low-risk, and is widely shared in patient communities as a gentle immune "reset."

What the evidence shows

There are no published randomized outcome trials of LDN in Hashimoto’s; the case rests on mechanism and patient reports. A phase-2 placebo-controlled trial (ThyroLDN) is now testing it. Until it reports, this is unproven — the LDN entry above has the detail.

In our practice

We don’t currently offer LDN for Hashimoto’s. When the trial reports, we’ll read it carefully and revise in either direction.

EvidenceGrade E · Insufficientawaiting the first outcome trial.
Can red-light or low-level laser therapy improve Hashimoto’s? Grade D · Experimental
Intriguing but unproven. A few small studies reported reduced antibodies or lower dose needs, but the work is limited, largely from one group, and not independently replicated.

Why patients ask this

The early studies got attention, and light therapy is noninvasive and appealing.

What the evidence shows

Small trials — mostly from a single research group — suggested effects on antibody levels and levothyroxine requirement, but the evidence base is thin, not replicated, and clinical-outcome data are limited. A promising signal, not established therapy.

In our practice

We watch this space but don’t offer red-light therapy as a Hashimoto’s treatment; the evidence isn’t there yet.

EvidenceGrade D · Experimentalan early, unreplicated signal.
Does ozone therapy help Hashimoto’s? Grade E · Insufficient
No. Ozone therapy has no controlled evidence in Hashimoto’s and carries real safety concerns depending on how it’s given.

Why patients ask this

It’s marketed broadly as an oxidative "immune booster," and a lack of good options makes it tempting.

What the evidence shows

There are no controlled trials supporting ozone therapy for autoimmune thyroid disease; it’s an unproven intervention with documented risks. Mechanistic claims don’t substitute for outcome data.

In our practice

We don’t use or recommend ozone therapy for Hashimoto’s.

EvidenceGrade E · Insufficientfor ozone therapy in Hashimoto’s.
Can stem cells treat autoimmune thyroid disease? Grade E · Insufficient
Not yet — it’s a research idea. Functional thyroid tissue has been grown from stem cells in animal models, but there is nothing clinical for Hashimoto’s.

Why patients ask this

Regenerative medicine is genuinely exciting, and "regrow the gland" is a hopeful headline.

What the evidence shows

Stem-cell-derived thyroid tissue is early laboratory and animal-model work, not a human therapy; commercial "stem cell" offerings for autoimmune disease are unproven and sometimes unsafe (the regeneration entry above has more).

In our practice

We treat this as a long-horizon research direction, not an option now — and we’d steer you away from commercial stem-cell clinics.

EvidenceGrade E · Insufficientpreclinical only.
Are peptide therapies effective for Hashimoto’s? Grade E · Insufficient
No evidence for Hashimoto’s. "Peptide therapies" are a broad, largely unregulated category with no controlled outcome data in autoimmune thyroid disease.

Why patients ask this

Peptides are marketed heavily for immunity, healing, and longevity, often with confident claims.

What the evidence shows

The various peptides sold for immune modulation lack controlled trials in Hashimoto’s, and their quality, purity, and safety are frequently unregulated. Mechanistic and anecdotal claims aren’t outcome evidence.

In our practice

We don’t use peptide therapies for Hashimoto’s outside of a legitimate clinical trial.

EvidenceGrade E · Insufficientfor peptide therapies in Hashimoto’s.
Should everyone take low-dose immunomodulators? Grade E · Insufficient
No — not as a general strategy. There’s no evidence that broad low-dose immune-modulating regimens help Hashimoto’s, and suppressing immunity has real costs.

Why patients ask this

Since Hashimoto’s is autoimmune, "calm the immune system" sounds like it should be the answer.

What the evidence shows

Outside of specific, studied agents, blanket low-dose immunomodulation has no outcome evidence in Hashimoto’s, and immune suppression carries infection and other risks that aren’t justified for a condition managed well and safely with hormone replacement.

In our practice

We manage the thyroid deficit Hashimoto’s causes; we don’t use unproven immune-modulating regimens to chase antibodies.

EvidenceGrade E · Insufficientfor routine low-dose immunomodulation.
Can biologic drugs cure Hashimoto’s? Grade E · Insufficient
No. No biologic drug is approved or shown to cure Hashimoto’s, and the trade-offs of immune-targeted drugs aren’t justified for a condition replaced safely with a daily tablet.

Why patients ask this

Biologics have transformed other autoimmune diseases, so it’s reasonable to ask why not this one.

What the evidence shows

Biologics targeting immune pathways haven’t demonstrated cure or meaningful disease modification in Hashimoto’s, and their risks and cost are hard to justify when levothyroxine already replaces what’s lost simply and safely. This could change if targeted trials succeed.

In our practice

We follow the research, but there’s no biologic we’d use to treat or "cure" Hashimoto’s today.

EvidenceGrade E · Insufficientfor biologics to cure Hashimoto’s.

Continue across the knowledge base

TreatmentNutrition & LifestyleCauses & PathogenesisThe Autoimmune Spectrum

Ready for thyroid care that takes your questions seriously?

Board-certified endocrinologists. Physician-scientists. Straight answers about what works and what does not.

Request an Appointment 858-622-7200
Call Request Appointment
One San Diego endocrine group, specialized centers: Diabetes & Endocrine Specialists · SanDiEndo — Interventional Endocrinology · MenoExperts — Menopause & Midlife · HashiExperts — Hashimoto's Care · EndoTrials — Clinical Research